matthias steger, phd mba

ceo and co-founder

Matthias Steger’s long career in pharma and biotech began with F. Hoffmann-La Roche in 1999, when he worked in the design and synthesis of active molecules for a variety of therapeutic indications - next, he joined Axovan (later acquired by Actelion), where he built and implemented a new platform for orphan GPCR drug discovery - Matthias then branched out into investment banking at Kepler Equities before returning to Roche in 2007 - he became the firm’s global head of research and technology partnering, a role in which he instigated and managed more than 50 collaborations - in 2015 he followed his strong entrepreneurial instincts, first establishing SequelBlu, an independent advisory firm aimed at assisting companies with sustainable innovation, and then endogena.
Matthias earned his MSc in organic chemistry and biochemistry at the University of Zurich, and his PhD in medicinal chemistry at the University of Sussex. In 2005 he completed an MBA at the University of St Gallen, where he was awarded Dean’s Honors.

bernhard fasching, phd

vp medicinal chemistry

Bernhard Fasching is a highly motivated scientist with a decade’s experience in academic research, pre-clinical project leadership, and drug discovery, resulting in several projects that Bernhard successfully progressed to clinical candidates.
his career began with a PhD at the Max-Planck-Institute for Coal Research in Mühlheim, Germany, followed by a two-year postdoc at Memorial Sloan-Kettering Cancer Center in New York, where he worked on in glycopeptide synthesis. In 2010, Bernhard began his industrial career at F. Hoffmann-La Roche in Basel as a senior scientist and project team leader for early-stage CNS drug development programs - he joined endogena in 2016.

micha drukker, phd

vp stem cell biology

Micha Drukker is a principle investigator and the head of the human induced pluripotent stem cell core at the Helmholtz Institute in Munich. Micha is involved in basic and translational research in the stem cell field, and his achievements include the first analysis of the immunological properties of differentiated human embryonic stem (ES) cells, which has promoted the development of strategies to overcome the immunogenicity of human ES cells including by derivation of patient-matched pluripotent stem cells through therapeutic cloning and induction of pluripotency in somatic cells by reprogramming. More recently, Micha discovered cell surface markers enabling purification and monitoring of some of the earliest developmental progenitors from human ES cells mutually exclusively sorted from teratoma-initiating cells, and his most recent work focuses on the regulation of early pluripotent stem cell differentiation. Micha also leads projects aiming to produce and genetically engineer induced pluripotent stem cells for tissue restoration under clinical standards.
Micha earned his BSc and PhD at the Hebrew University of Jerusalem, and did postdoctoral work at Stanford University.